Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives

• Published in: Pharmaceuticals (Basel, Switzerland) Switzerland), 2023-09, Vol.16 (9), p.1266
• Main Authors: ElHady, Ahmed K, El-Gamil, Dalia S, Abdel-Halim, Mohammad, Abadi, Ashraf H
• Format: Article
• Language: English
• Subjects: Alfuzosin; Antimitotic agents; Antineoplastic agents; Avanafil; Blood platelets; Cancer; Care and treatment; Cystic fibrosis; Development and progression; Diabetes; Drug discovery; Drug resistance; Drug therapy; Epoprostenol; Erectile dysfunction; FDA approval; Health aspects; Impotence; Kinases; Nitric oxide; NO/cGMP; Penis; Pharmacokinetics; phosphodiesterase 5 inhibitors; Phosphorylation; Physiological aspects; Physiology; pulmonary arterial hypertension; Pulmonary arteries; Pulmonary hypertension; Review; Scleroderma (Disease); selectivity; Smooth muscle; Systemic scleroderma; Veins & arteries
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph16091266

Phosphodiesterase 5 (PDE5) inhibitors presented themselves as important players in the nitric oxide/cGMP pathway, thus exerting a profound impact on various physiological and pathological processes. Beyond their well-known efficacy in treating male erectile dysfunction (ED) and pulmonary arterial hypertension (PAH), a plethora of studies have unveiled their significance in the treatment of a myriad of other diseases, including cognitive functions, heart failure, multiple drug resistance in cancer therapy, immune diseases, systemic sclerosis and others. This comprehensive review aims to provide an updated assessment of the crucial role played by PDE5 inhibitors (PDE5-Is) as disease-modifying agents taking their limiting side effects into consideration. From a medicinal chemistry and drug discovery perspective, the published PDE5-Is over the last 10 years and their binding characteristics are systemically discussed, and advancement in properties is exposed. A persistent challenge encountered with these agents lies in their limited isozyme selectivity; considering this obstacle, this review also highlights the breakthrough development of the recently reported PDE5 allosteric inhibitors, which exhibit an unparalleled level of selectivity that was rarely achievable by competitive inhibitors. The implications and potential impact of these novel allosteric inhibitors are meticulously explored. Additionally, the concept of multi-targeted ligands is critically evaluated in relation to PDE5-Is by inspecting the broader spectrum of their molecular interactions and effects. The objective of this review is to provide insight into the design of potent, selective PDE5-Is and an overview of their biological function, limitations, challenges, therapeutic potentials, undergoing clinical trials, future prospects and emerging uses, thus guiding upcoming endeavors in both academia and industry within this domain.